KLOW
Not medical advice
Describes a named combination people search for — not a prescription. See the Disclaimer.
What It Is
“KLOW” is the GLOW blend plus KPV — the same skin-and-healing base with an added anti-inflammatory tripeptide. The “K” is for KPV. It targets Skin & Hair and Recovery like GLOW, with an added emphasis on inflammation and Gut Health. Components:
- KPV — an anti-inflammatory tripeptide (C-terminal fragment of α-MSH) studied in cell/animal colitis models; the added “K”.
- GHK-Cu — copper tripeptide for skin/collagen remodeling.
- BPC-157 — pentadecapeptide for soft-tissue and gut healing.
- TB-500 — Thymosin Beta-4 fragment for cell migration/repair.
It is typically sold pre-mixed as a four-peptide vial (a frequently reported make-up is ~50 mg GHK-Cu : 10 mg KPV : 10 mg BPC-157 : 10 mg TB-500, totaling ~80 mg).
Why People Combine These
The rationale is to add anti-inflammatory coverage to GLOW:
- The GLOW base provides skin remodeling (GHK-Cu) plus soft-tissue repair (BPC-157 + TB-500).
- KPV adds NF-κB-pathway anti-inflammatory signaling, which is the rationale for using it in skin (calmer skin) and gut (colitis-model data) contexts.
- The pitch is a single “calm, repair, and glow” blend covering inflammation, healing, and appearance.
Evidence strength
No published human trial has tested these four together. KPV’s anti-inflammatory data is Preclinical (cell/rodent); GHK-Cu has small topical human data; BPC-157 and TB-500 are Preclinical. The four-peptide injectable combination is Anecdotal. See Side Effects & Risk Management.
Reported Dosing
As reported, not advice
Protocols below are as reported in community/vendor sources for a pre-mixed blend, not a clinical regimen. There is no established human therapeutic dose. See Reconstitution & Dosing Math and Cycling.
| Component | Reported dose | Frequency | Notes |
|---|---|---|---|
| Total KLOW blend | ~4 mg total/dose | 5×/week loading → 3×/week maintenance (SC) | E.g. 10 units of a ~40 mg/mL reconstitution |
| GHK-Cu (in blend) | ~2.5 mg/dose | per dose | The bulk of the blend |
| KPV (in blend) | ~0.5 mg/dose | per dose | Anti-inflammatory share |
| BPC-157 (in blend) | ~0.5 mg/dose | per dose | Per-peptide share |
| TB-500 (in blend) | ~0.5 mg/dose | per dose | Per-peptide share |
Reported cycles run roughly 8–12 weeks on, then 4–8 weeks off, with a loading-then-maintenance frequency taper. Smaller per-unit dosing (~267 µg total/unit) is also described for titration. See Cycling.
Combined Risks & Considerations
- Four-peptide uncertainty. Stacking four compounds with limited (injectable) human safety data maximizes the unknowns; an adverse reaction is hard to attribute to one component.
- Copper load. Daily/frequent GHK-Cu carries the same theoretical copper-accumulation concern as GLOW.
- Pro-angiogenic profile. GHK-Cu, BPC-157, and TB-500 are pro-angiogenic/remodeling in preclinical work; the speculative tumor-growth concern applies and is uncharacterized in humans.
- WADA-banned component. TB-500 is prohibited in sport (S2); tested athletes risk sanctions.
- Sourcing risk is highest here — four peptides hidden in one vial (see below).
- See Side Effects & Risk Management.
Sourcing
KLOW is sold pre-mixed as a four-peptide vial, the hardest configuration to verify: you cannot independently confirm four identities, the stated ratio, the copper content, or each fill weight from the outside. Before trusting any product:
- Vet the market and vendors: Sourcing
- Read the certificate of analysis: How to Read a CoA
- Watch for warning signs: Red Flags & Scams
No vendors are endorsed here.
FAQ
What does KLOW stand for? It is GLOW (GHK-Cu + BPC-157 + TB-500) with KPV added — “K” + “LOW/GLOW”.
Why add KPV to GLOW? KPV brings anti-inflammatory (NF-κB) signaling, used for calmer skin and gut-inflammation goals. See KPV.
Is KLOW FDA-approved? No. None of the four components is approved for injectable human use.
Is four peptides better than GLOW’s three? “More components” is not validated as more effective; it adds anti-inflammatory rationale but also more uncertainty and sourcing risk.
References
- Brzoska T. et al. (2008). “α-MSH and related tripeptides: anti-inflammatory and protective effects.” Endocrine Reviews.
- Kannengiesser K. et al. (2008). “Melanocortin-derived tripeptide KPV in murine models of inflammatory bowel disease.” Inflammatory Bowel Diseases.
- Pickart L., Margolina A. (2018). “Regenerative and protective actions of the GHK-Cu peptide.” International Journal of Molecular Sciences.
- Gwyer D., Wragg N.M., Wilson S.L. (2019). “Gastric pentadecapeptide BPC 157 and soft tissue healing.” Cell and Tissue Research.
- Goldstein A.L. et al. (2005). “Thymosin β4 and tissue repair.” Trends in Molecular Medicine.
← Stacks · Home Educational information only — not medical advice. See Disclaimer.